Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

103951 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-01

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Over the past 40 years, new types of insulins have been marketed to mirror the effect of endogenous insulin. With the existing long-acting insulin product patents expiring and the FDA approval of new biosimilar and innovator insulins, adults with diabetes and their physicians will have additional therapeutic options. This observational study will describe the patient characteristics of new and existing users of long-acting or intermediate acting insulins with and without oral anti-diabetic agents (OAD) as well as acute hypoglycemic episodes, acute cardiac events, and A1C measures. The Biologic and Biosimilars Collective Intelligence Consortium (BBCIC) will use the findings from this descriptive analysis to design a comparative study evaluating the real-world effectiveness and safety of biosimilar and innovator insulins.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

NCT00191464

Diabetes Mellitus, Type 2

COMPLETED PHASE4

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649

Type 2 Diabetes Mellitus

COMPLETED PHASE4

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

NCT01790438

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus

NCT02680457

Type 2 Diabetes Mellitus

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Additional information:

This protocol was designed as a descriptive analysis, not to support a hypothesis. This information is being provided to the public in the interest of transparency and for demonstrating the BBCIC's Distributed Research Network's (DRN) ability to define exposures, outcomes, covariates and confounders. When published, the report will caution that the protocol does not support any ability to compare safety or effectiveness but instead is to be used only to explore the feasibility of future, more detailed comparative analyses and to better understand the capabilities of the BBCIC project. Further, the report will caution that information from this protocol should not affect use of the medical products described in any way and the fact that the BBCIC is performing this descriptive analysis in no way suggests there is a safety or effectiveness issue with any of the products described.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes Type 1

Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins

Long- and intermediate- acting insulins

Intervention Type DRUG

alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea

Diabetes Type 2

Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins

Long- and intermediate- acting insulins

Intervention Type DRUG

alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Long- and intermediate- acting insulins

alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NPH, Lantus, Levemir, Toujeo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with baseline period of 183 days with continuous medical and pharmacy coverage preceding the first prescription fill
* new and current users of the following exposures

* Long-acting insulin (insulin detemir, glargine) alone or with metformin (LAI)
* Long-acting insulin (insulin detemir, glargine) plus rapid/short acting insulin (with or without metformin) (LAI+R)
* Long-acting insulin (insulin detemir, glargine) plus second-generation sulfonylurea agent (Glimepiride, Glipizide, Glipizide/Metformin, Glyburide, Glyburide/Metformin) (with or without metformin) (LAI+sulfa)
* NPH insulin (Humulin, Novolin) alone or with metformin (NPH)
* NPH insulin (Humulin, Novolin) plus rapid/short acting insulin (with or without metformin) (NHP+R)
* NPH insulin (Humulin, Novolin) plus second-generation sulfonylurea agent (Glimepiride, Glipizide, Glipizide/Metformin, Glyburide, Glyburide/Metformin (with or without metformin) (NPH + sulfa)

Exclusion Criteria

* Adult patients with diabetes with health insurance evidence of insulin pumps and/ or insulin pump supplies, gestational diabetes, liver disorders, dialysis, end-stage renal disease (ESRD), amputations, hemoglobinopathy, hemolytic anemia, or sickle cell anemia or transfusion
* Emergency Department (ED) visit for hypoglycemia; hospitalization or ED visit for cardiovascular event (stroke, acute myocardial infarction, unstable angina or diagnosis consistent with unstable angina -- i.e., occlusion without infarction or coronary insufficiency).
* Adult patients with diabetes on any other insulins except cohort insulins (i.e., rapid/short unless in combinations above).\*
* Adult patients with diabetes on first-generation sulfonylureas, Dipeptidyl peptidase-4 (DPP4), Glucagon-like Peptide (GLP), Sodium-glucose cotransporter-2 (SGLT-2) or Thiazolidinediones (TZD) agents, alone or in combination with cohort defining drugs\*:

* First generation sulfonylurea agents (chlorpropamide, tolazamide )
* TZDs (pioglitazone, pioglitazone/metformin, rosiglitazone, rosiglitazone/metformin
* DPP4s (sitagliptin, saxagliptin, linagliptin, alogliptin)
* GLP1 (exenatide, liraglutide, dulaglutide)
* SGLT-2 (empagliflozin, canagliflozin, dapagliflozin)

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No